Market Cap (In USD)
1.53 Million
Revenue (In USD)
-
Net Income (In USD)
-98.29 Million
Avg. Volume
866.47 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.98-25.0
- PE
- -0.07
- EPS
- -8.48
- Beta Value
- 0.639
- ISIN
- US98987D2018
- CUSIP
- -
- CIK
- 1859007
- Shares
- 2568191.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Stephen C. Glover
- Employee Count
- -
- Website
- https://www.zyversa.com
- Ipo Date
- 2022-02-11
- Details
- ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
More Stocks
-
VSEEVSee Health, Inc.
VSEE
-
IDKOYIdemitsu Kosan Co.,Ltd.
IDKOY
-
GVR
-
FFXDF
-
PRIO3Petro Rio S.A.
PRIO3
-
FFNT
-
MALEE
-
FEMYFemasys Inc.
FEMY